Human genetics is reshaping drug discovery by revealing reliable targets, improving success rates, and reducing costly clinical failures in the development of safer, more effective treatments.

MAP, a knowledge-driven AI from Shanghai Jiao Tong, predicts single-cell responses for unprofiled drugs, prioritizing four of five approved cancer drugs in zero-shot tests.

GOLLuM trains LLMs using Bayesian uncertainty signals, raising high-yield Buchwald-Hartwig discovery from 24% to 43% in 50 experiments across 19 benchmarks.

Alzheimer's candidate KCL-286 repairs neuronal DNA damage, cuts neuroinflammation in mice. Safe for humans, this amyloid alternative targets multiple pathways.

InnoCare's TYK2 inhibitor soficitinib hits vitiligo Phase 2 endpoint, advancing to Phase 3. Competitive autoimmune skin disorder trial shows strong F-VASI improvement.

AI-driven drug discovery is transforming biotechnology as Big Tech acquires biotech startups, redefining pharmaceutical innovation and the future of AI-powered healthcare.

AI-driven drug discovery fueled 26 novel FDA therapy approvals in early 2026, delivering breakthrough cancer treatments and first-ever options for rare neurological disorders.

An AI-designed drug has entered Phase III trials, bringing the pharmaceutical industry closer to its first medicine invented entirely by artificial intelligence.

Researchers developed six novel drugs aimed at killing resistant bacteria strains linked to 5 million deaths a year

AI creates effective drug candidates by analyzing only the target protein's structure, potentially reducing costs and time in developing treatments for diseases like cancer.